The 5-hydroxytryptamine 2A receptor (HTR2A), a G protein-coupled receptor, mediates serotonin signaling in the central nervous system and peripheral tissues. It plays key roles in regulating mood, cognition, sensory processing, and vascular function. Dysregulation of HTR2A is implicated in psychiatric disorders, including schizophrenia, depression, and anxiety, making it a target for antipsychotics, antidepressants, and psychedelics. HTR2A antibodies are essential tools for studying receptor expression, localization, and signaling mechanisms. They are widely used in techniques like immunohistochemistry, Western blotting, and flow cytometry to map receptor distribution in brain regions (e.g., cortex, hippocampus) or peripheral cells. However, challenges exist due to the receptor's structural homology with related subtypes (e.g., HTR2B/2C), requiring rigorous validation of antibody specificity through knockout controls or blocking peptides. Some antibodies target extracellular epitopes for live-cell applications, while others detect intracellular domains for fixed samples. Recent advances in cryo-EM and HTR2A-selective ligands have spurred renewed interest in developing high-precision antibodies for translational research, particularly in neuropharmacology and biomarker discovery for mental health disorders. Proper validation remains critical to avoid cross-reactivity artifacts in experimental models.